Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senna

This article was originally published in The Tan Sheet

Executive Summary

NDMA asks FDA in a Sept. 17 letter to keep the administrative record open for senna as a Category I laxative ingredient until a proposed two-year carcinogenicity study is completed. Concern regarding the safety of senna prompted FDA to request additional data on the ingredient in a June 19 Federal Register notice ("The Tan Sheet" June 22, p. 6). The deadline for the submission of new data is June 21 next year. NDMA asserts, however, the required studies cannot be finished in a year. "To complete the in-life portion of a long-term rodent study requires at least two years, and that must be preceded by preliminary studies and followed by time-consuming histopathologic examinations and analysis of other endpoints," NDMA points out. The proposed rule also applies to bisacodyl, cascara sagrada and aloe

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel